Developer docs
API playgroundTry for free, no card

Search company profiles

Osel

Full company profile

uuid000bi6j

Namestring
Osel
Legal namestring
Osel Inc.
Websiteurl
oselinc.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Osel Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Mountain View, California, that is pioneering the development of Live Biotherapeutic Products (LBPs) — rigorously selected, single-strain live microorganisms engineered to prevent or treat disease by restoring healthy microbiome communities. The company filed its first IND with the FDA in 2003 for clinical testing of a live biotherapeutic, well before the FDA formally defined the LBP category in 2012, establishing it as a first mover in this regulatory class. Osel differentiates its single-strain products from fecal microbiota transplants and dietary probiotics on the basis of reproducibility, scalability, and biologic-drug-grade regulatory rigor.

Short descriptiontext

Osel Inc. is a clinical-stage biopharmaceutical company developing Live Biotherapeutic Products — engineered single-strain bacteria that restore healthy microbiome communities. The company targets women's health conditions (bacterial vaginosis, preterm birth) and oncology immunotherapy enhancement, and is headquartered in Mountain View, California.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live biotherapeutic products, microbiome therapeutics, biologic drug development, women's health microbiome, immuno-oncology microbiome
Industry2 codes
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Microbiome Therapeutics
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1LACTIN-V
Description

Live biotherapeutic product containing Lactobacillus crispatus CTV-05 for preventing recurrent bacterial vaginosis and preterm birth

oselinc.com
+4 more records
Core offering1 text field

Osel develops and commercializes Live Biotherapeutic Products (LBPs), which are FDA-regulated biologic drugs consisting of rigorously selected, single-strain live bacteria engineered to prevent or treat disease by restoring healthy microbiome communities. Its lead clinical-stage products are LACTIN-V, a vaginally administered Lactobacillus crispatus CTV-05 therapy for recurrent bacterial vaginosis and preterm birth prevention, and CBM588/MO-03, an orally administered Clostridium butyricum strain used to enhance cancer immunotherapy response. The company also advances the MucoCept platform for mucosal viral protection and the Gassericin K7 bacteriocin for cervical cancer, supported by proprietary bacterial strain libraries, screening methods, and formulation/manufacturing technologies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • LACTIN-V reduced BV recurrence to 30% vs 45% for placebo (p=0.01) in Phase 2b trial
+5 more records
Product overview1 text field

Osel is a clinical-stage biopharma company pioneering Live Biotherapeutic Products (LBPs) to prevent or treat conditions resulting from disruptions of the human microbiome. The company's portfolio includes LACTIN-V for women's health (bacterial vaginosis and preterm birth prevention), CBM588/MO-03 for oncology immunotherapy enhancement, Gassericin K7 for cervical cancer, and the MucoCept platform for mucosal viral protection. Osel focuses on rigorously selected single-strain products that are highly reproducible, scalable, and regulated as biologic drugs by the FDA, differentiating from fecal transplants and dietary probiotics.

Product and service5 records
1LACTIN-V
CategoryLive Biotherapeutic Products — Women's Health
Description

A live biotherapeutic product (LBP) containing Lactobacillus crispatus CTV-05, a hydrogen peroxide-producing vaginal Lactobacillus strain. Delivered vaginally with a proprietary applicator to restore protective vaginal microbiota in women suffering from recurrent bacterial vaginosis, and under development for prevention of recurrent urinary tract infections, preterm birth, and HPV/cervical dysplasia. A prescription biologic drug candidate.

2CBM588 (Clostridium butyricum MIYAIRI 588)
CategoryLive Biotherapeutic Products — Oncology / GI
Description

An orally administered live biotherapeutic product containing Clostridium butyricum MIYAIRI 588, which produces butyrate and other short-chain fatty acids with immunomodulatory activity. Originally developed for GI indications in Japan, being evaluated in the U.S. for antibiotic-associated diarrhea, C. difficile infection prevention, and as an immunotherapy enhancer for cancer treatment in combination with immune checkpoint inhibitors.

3MO-03
CategoryLive Biotherapeutic Products — Oncology
Description

A high-potency capsule formulation of CBM588 (Clostridium butyricum MIYAIRI 588) developed specifically for oncology applications. Being evaluated in the Phase 3 BIOFRONT pivotal trial for advanced and metastatic renal cell carcinoma in combination with immune checkpoint inhibitors, with favorable safety observed across higher dose levels and no increase in immune-related adverse events.

4Gassericin K7 Bacteriocin
CategoryLive Biotherapeutic Products — Oncology (Women's Cancers)
Description

A Class IIb two-peptide bacteriocin (GasK7A and GasK7B) under development that selectively inhibits Lactobacillus iners. GasK7B has nanomolar potency against L. iners and is being developed in collaboration with MD Anderson for cervical cancer treatment in conjunction with chemoradiation therapy to address tumor-specific chemoradiation resistance.

5MucoCept Technology Platform
CategoryLive Biotherapeutic Platform — Mucosal Viral Protection
Description

A proprietary technology platform that harnesses and enhances the human microbiome by modifying commensal Lactobacillus to express potent inhibitors of viral pathogens at mucosal surfaces. Proof of concept demonstrated for HIV-1 prevention in women (MucoCept-HIV), with an IND filed with FDA for first-in-human clinical study.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Partnership for FLIP-2 Phase 2b clinical trial evaluating LACTIN-V in pregnant women at high risk of preterm birth. March of Dimes provides funding support and access to their Prematurity Research Center at Imperial College London.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Imperial Clinical Trials Unit conducting FLIP-2 Phase 2b trial of LACTIN-V for preterm birth prevention. Led by Dr. Lynne Sykes, Professor Phillip Bennett, and Dr. Ryan Love. Trial enrolls 360 pregnant patients across four UK maternity units.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Clinical trial agreement for pivotal Phase 3 BIOFRONT trial of MO-03 (CBM588) in combination with standard immuno-oncology regimens for advanced and metastatic renal cell carcinoma. Supported by National Cancer Institute. Trial to enroll approximately 700 patients across up to 150 SWOG sites in the US, initiating Q1 2026.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-02-03
Description

Exclusive worldwide license to inventions from investigator-initiated Phase 2 trial of LACTIN-V in women undergoing in-vitro fertilization. Ongoing Phase 2 IVF trial conducted at four Danish fertility clinics led by Professor Peter Humaidan.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple clinical trials of CBM588 in combination with immune checkpoint inhibitors for metastatic renal cell carcinoma. City of Hope conducted Phase 1 studies demonstrating improved PFS and response rates. Dr. Sumanta Pal leads the kidney cancer program.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed exclusive rights for pharmaceutical use of CBM588 (Clostridium butyricum MIYAIRI 588) in the United States, Canada, and Europe. Miyarisan manufactures CBM588 under GMP and markets it as prescription product MIYA-BM in Japan. Supplied GMP product for oncology trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on Gassericin K7B bacteriocin research. MD Anderson's Laboratory of Lauren Colbert discovered oncogenic L. iners strains associated with cervical cancer progression and poor survival. Collaborating to synthesize GasK7B and establish it as a potential drug candidate.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Provides support for the BIOFRONT Phase 3 trial of MO-03 in metastatic renal cell carcinoma as part of the National Institutes of Health infrastructure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration since 2007 with Dr. Craig Cohen in clinical development of LACTIN-V through Phase 1, 2a, and 2b studies. Dr. Cohen served as principal investigator on NIAID/NIH grants for MucoCept-CVN development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Funding support for FLIP-2 preterm birth prevention trial of LACTIN-V, part of the UK National Institute for Health and Care Research infrastructure.

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed orally delivered, single-strain microbial medicines (SINTAX platform) for immune-mediated diseases including oncology and inflammatory indications. Direct peer to Osel in the microbe-based immunomodulation therapeutic approach.

TypeDirect peer
Description

Pioneer microbiome therapeutics company that developed VOWST (SER-109), the first FDA-approved oral LBP for prevention of recurrent C. difficile infection in adults. Direct precedent for LBP regulatory pathway, manufacturing, and commercial playbooks relevant to Osel.

TypeDirect peer
Description

European clinical-stage microbiome biotherapeutics company developing standardized, full-ecosystem LBPs (e.g., MaaT013 for GvHD) with oncology overlap. Comparable to Osel in developing rigorous, GMP-manufactured bacterial therapies with regulatory-grade data.

TypeDirect peer
Description

Was a clinical-stage microbiome therapeutics company developing Full-Spectrum Microbiota (FMP) products for recurrent C. difficile and other dysbiosis indications. Direct peer in the live biotherapeutic / microbiome drug category with overlapping clinical trial and regulatory considerations.

TypeDirect peer
Description

Clinical-stage developer of defined Live Biotherapeutic Products (VE303, VE202) for C. difficile and IBD. Closely comparable to Osel as a Boston/Cambridge-based LBP company advancing single-strain and consortia bacterial drugs through FDA-regulated trials.

TypeDirect peer
Description

Clinical-stage microbiome-focused company developing engineered microbial therapies, including work with gamma-delta T cells and oral microbiome candidates. Comparable to Osel as a clinical-stage developer advancing engineered/consortium bacterial candidates into FDA-regulated trials.

TypeDirect peer
Description

UK-based clinical-stage microbiome therapeutics company (acquired by AbbVie in 2023) developing Live Biotherapeutic Products including Blautix for IBS and oncology candidates. Comparable to Osel in clinical-stage LBP development, including regulatory engagement and bacterial strain selection.

TypeDirect peer
Description

Ferring's Rebiotix unit developed Rebyota (RBX2660), an FDA-approved live biotherapeutic for prevention of recurrent C. difficile. Comparable to Osel as a developer of FDA-regulated live biotherapeutic products with a similar clinical development and scale-up profile.

9Axial Therapeutics
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing gut-brain-axis targeted microbiome-based therapeutics for neurological and neurodevelopmental disorders. Comparable to Osel in being a clinical-stage venture-backed microbiome therapeutics developer with a strain-specific, FDA-regulated drug approach.

10Kaleido Biosciences
TypeDirect peer
Description

Was a clinical-stage microbiome metabolic therapies company developing novel chemistries derived from the microbiome. Comparable to Osel as a clinical-stage microbiome drug developer pursuing FDA-regulated live biotherapeutic and metabolite therapeutic approaches across multiple indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Osel

Microbiome Therapeuticsoselinc.com

Osel Inc. is a clinical-stage biopharmaceutical company developing Live Biotherapeutic Products — engineered single-strain bacteria that restore healthy microbiome communities. The company targets women's health conditions (bacterial vaginosis, preterm birth) and oncology immunotherapy enhancement, and is headquartered in Mountain View, California.

What Osel does

Osel Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Mountain View, California, that is pioneering the development of Live Biotherapeutic Products (LBPs) — rigorously selected, single-strain live microorganisms engineered to prevent or treat disease by restoring healthy microbiome communities. The company filed its first IND with the FDA in 2003 for clinical testing of a live biotherapeutic, well before the FDA formally defined the LBP category in 2012, establishing it as a first mover in this regulatory class. Osel differentiates its single-strain products from fecal microbiota transplants and dietary probiotics on the basis of reproducibility, scalability, and biologic-drug-grade regulatory rigor.

Osel firmographics

Firmographics
Name
Osel
Legal name
Osel Inc.
Website
https://oselinc.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Osel Inc. is a clinical-stage biopharmaceutical company developing Live Biotherapeutic Products — engineered single-strain bacteria that restore healthy microbiome communities. The company targets women's health conditions (bacterial vaginosis, preterm birth) and oncology immunotherapy enhancement, and is headquartered in Mountain View, California.
Ownership category
akta.pro rank

Osel industry classification

Industry
Product category
Microbiome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)

Keywords

  • Live biotherapeutic products
  • Microbiome therapeutics
  • Biologic drug development
  • Women's health microbiome
  • Immuno-oncology microbiome

Where Osel is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Osel business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels4 records

Osel product offering

Product offering

Core offering

Osel develops and commercializes Live Biotherapeutic Products (LBPs), which are FDA-regulated biologic drugs consisting of rigorously selected, single-strain live bacteria engineered to prevent or treat disease by restoring healthy microbiome communities. Its lead clinical-stage products are LACTIN-V, a vaginally administered Lactobacillus crispatus CTV-05 therapy for recurrent bacterial vaginosis and preterm birth prevention, and CBM588/MO-03, an orally administered Clostridium butyricum strain used to enhance cancer immunotherapy response. The company also advances the MucoCept platform for mucosal viral protection and the Gassericin K7 bacteriocin for cervical cancer, supported by proprietary bacterial strain libraries, screening methods, and formulation/manufacturing technologies.

Product overview

Osel is a clinical-stage biopharma company pioneering Live Biotherapeutic Products (LBPs) to prevent or treat conditions resulting from disruptions of the human microbiome. The company's portfolio includes LACTIN-V for women's health (bacterial vaginosis and preterm birth prevention), CBM588/MO-03 for oncology immunotherapy enhancement, Gassericin K7 for cervical cancer, and the MucoCept platform for mucosal viral protection. Osel focuses on rigorously selected single-strain products that are highly reproducible, scalable, and regulated as biologic drugs by the FDA, differentiating from fecal transplants and dietary probiotics.

Differentiator

Problem solved

Functional benefit

Brands

  • LACTIN-V: Live biotherapeutic product containing Lactobacillus crispatus CTV-05 for preventing recurrent bacterial vaginosis and preterm birth
  • CBM588
  • MO-03
  • Gassericin K7B Bacteriocin
  • MucoCept Technology Platform

Products and services

  • LACTIN-V A live biotherapeutic product (LBP) containing Lactobacillus crispatus CTV-05, a hydrogen peroxide-producing vaginal Lactobacillus strain. Delivered vaginally with a proprietary applicator to restore protective vaginal microbiota in women suffering from recurrent bacterial vaginosis, and under development for prevention of recurrent urinary tract infections, preterm birth, and HPV/cervical dysplasia. A prescription biologic drug candidate.
  • CBM588 (Clostridium butyricum MIYAIRI 588) An orally administered live biotherapeutic product containing Clostridium butyricum MIYAIRI 588, which produces butyrate and other short-chain fatty acids with immunomodulatory activity. Originally developed for GI indications in Japan, being evaluated in the U.S. for antibiotic-associated diarrhea, C. difficile infection prevention, and as an immunotherapy enhancer for cancer treatment in combination with immune checkpoint inhibitors.
  • MO-03 A high-potency capsule formulation of CBM588 (Clostridium butyricum MIYAIRI 588) developed specifically for oncology applications. Being evaluated in the Phase 3 BIOFRONT pivotal trial for advanced and metastatic renal cell carcinoma in combination with immune checkpoint inhibitors, with favorable safety observed across higher dose levels and no increase in immune-related adverse events.
  • Gassericin K7 Bacteriocin A Class IIb two-peptide bacteriocin (GasK7A and GasK7B) under development that selectively inhibits Lactobacillus iners. GasK7B has nanomolar potency against L. iners and is being developed in collaboration with MD Anderson for cervical cancer treatment in conjunction with chemoradiation therapy to address tumor-specific chemoradiation resistance.
  • MucoCept Technology Platform A proprietary technology platform that harnesses and enhances the human microbiome by modifying commensal Lactobacillus to express potent inhibitors of viral pathogens at mucosal surfaces. Proof of concept demonstrated for HIV-1 prevention in women (MucoCept-HIV), with an IND filed with FDA for first-in-human clinical study.

Quantifiable outcome

  • LACTIN-V reduced BV recurrence to 30% vs 45% for placebo (p=0.01) in Phase 2b trial
  • +5 more outcomes

Companies that use Osel

Customer profile

Segments2 records

Ideal customer profiles2 records

Osel technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Osel partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • March of DimescoreStrategic or Co-development Partner · 13 May 2026Partnership for FLIP-2 Phase 2b clinical trial evaluating LACTIN-V in pregnant women at high risk of preterm birth. March of Dimes provides funding support and access to their Prematurity Research Center at Imperial College London.
  • Imperial College LondoncoreStrategic or Co-development Partner · 13 May 2026Imperial Clinical Trials Unit conducting FLIP-2 Phase 2b trial of LACTIN-V for preterm birth prevention. Led by Dr. Lynne Sykes, Professor Phillip Bennett, and Dr. Ryan Love. Trial enrolls 360 pregnant patients across four UK maternity units.
  • SWOG Cancer Research NetworkcoreStrategic or Co-development Partner · 8 January 2026Clinical trial agreement for pivotal Phase 3 BIOFRONT trial of MO-03 (CBM588) in combination with standard immuno-oncology regimens for advanced and metastatic renal cell carcinoma. Supported by National Cancer Institute. Trial to enroll approximately 700 patients across up to 150 SWOG sites in the US, initiating Q1 2026.
  • Aarhus University, Skive Hospital, Statens Serum Institut (Denmark)minorStrategic or Co-development Partner · 3 February 2021Exclusive worldwide license to inventions from investigator-initiated Phase 2 trial of LACTIN-V in women undergoing in-vitro fertilization. Ongoing Phase 2 IVF trial conducted at four Danish fertility clinics led by Professor Peter Humaidan.
  • City of Hope Comprehensive Cancer CentercoreStrategic or Co-development PartnerMultiple clinical trials of CBM588 in combination with immune checkpoint inhibitors for metastatic renal cell carcinoma. City of Hope conducted Phase 1 studies demonstrating improved PFS and response rates. Dr. Sumanta Pal leads the kidney cancer program.
  • Miyarisan Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing PartnerLicensed exclusive rights for pharmaceutical use of CBM588 (Clostridium butyricum MIYAIRI 588) in the United States, Canada, and Europe. Miyarisan manufactures CBM588 under GMP and markets it as prescription product MIYA-BM in Japan. Supplied GMP product for oncology trials.
  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerCollaboration on Gassericin K7B bacteriocin research. MD Anderson's Laboratory of Lauren Colbert discovered oncogenic L. iners strains associated with cervical cancer progression and poor survival. Collaborating to synthesize GasK7B and establish it as a potential drug candidate.
  • National Cancer InstitutecoreStrategic or Co-development PartnerProvides support for the BIOFRONT Phase 3 trial of MO-03 in metastatic renal cell carcinoma as part of the National Institutes of Health infrastructure.
  • UCSF (University of California San Francisco)coreStrategic or Co-development PartnerLong-standing collaboration since 2007 with Dr. Craig Cohen in clinical development of LACTIN-V through Phase 1, 2a, and 2b studies. Dr. Cohen served as principal investigator on NIAID/NIH grants for MucoCept-CVN development.
  • NIHR Imperial Biomedical Research CentreminorStrategic or Co-development PartnerFunding support for FLIP-2 preterm birth prevention trial of LACTIN-V, part of the UK National Institute for Health and Care Research infrastructure.

Scale indicators5 records

Expansion highlights5 records

Osel competitors and assessment

Company assessment

Direct peers

  • Evelo Biosciences: Developed orally delivered, single-strain microbial medicines (SINTAX platform) for immune-mediated diseases including oncology and inflammatory indications. Direct peer to Osel in the microbe-based immunomodulation therapeutic approach.
  • Seres Therapeutics: Pioneer microbiome therapeutics company that developed VOWST (SER-109), the first FDA-approved oral LBP for prevention of recurrent C. difficile infection in adults. Direct precedent for LBP regulatory pathway, manufacturing, and commercial playbooks relevant to Osel.
  • MaaT Pharma: European clinical-stage microbiome biotherapeutics company developing standardized, full-ecosystem LBPs (e.g., MaaT013 for GvHD) with oncology overlap. Comparable to Osel in developing rigorous, GMP-manufactured bacterial therapies with regulatory-grade data.
  • Finch Therapeutics: Was a clinical-stage microbiome therapeutics company developing Full-Spectrum Microbiota (FMP) products for recurrent C. difficile and other dysbiosis indications. Direct peer in the live biotherapeutic / microbiome drug category with overlapping clinical trial and regulatory considerations.
  • Vedanta Biosciences: Clinical-stage developer of defined Live Biotherapeutic Products (VE303, VE202) for C. difficile and IBD. Closely comparable to Osel as a Boston/Cambridge-based LBP company advancing single-strain and consortia bacterial drugs through FDA-regulated trials.
  • Assembly Biosciences: Clinical-stage microbiome-focused company developing engineered microbial therapies, including work with gamma-delta T cells and oral microbiome candidates. Comparable to Osel as a clinical-stage developer advancing engineered/consortium bacterial candidates into FDA-regulated trials.
  • 4D Pharma (AbbVie): UK-based clinical-stage microbiome therapeutics company (acquired by AbbVie in 2023) developing Live Biotherapeutic Products including Blautix for IBS and oncology candidates. Comparable to Osel in clinical-stage LBP development, including regulatory engagement and bacterial strain selection.
  • Ferring Pharmaceuticals (Rebiotix): Ferring's Rebiotix unit developed Rebyota (RBX2660), an FDA-approved live biotherapeutic for prevention of recurrent C. difficile. Comparable to Osel as a developer of FDA-regulated live biotherapeutic products with a similar clinical development and scale-up profile.
  • Axial Therapeutics: Clinical-stage biopharmaceutical company developing gut-brain-axis targeted microbiome-based therapeutics for neurological and neurodevelopmental disorders. Comparable to Osel in being a clinical-stage venture-backed microbiome therapeutics developer with a strain-specific, FDA-regulated drug approach.
  • Kaleido Biosciences: Was a clinical-stage microbiome metabolic therapies company developing novel chemistries derived from the microbiome. Comparable to Osel as a clinical-stage microbiome drug developer pursuing FDA-regulated live biotherapeutic and metabolite therapeutic approaches across multiple indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Osel social profiles

Digital presence

Osel financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Osel leadership team

Management profile

Number of profiles

Profiles5 records

Osel funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Osel M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osel

What does Osel do?

Osel develops and commercializes Live Biotherapeutic Products (LBPs), which are FDA-regulated biologic drugs consisting of rigorously selected, single-strain live bacteria engineered to prevent or treat disease by restoring healthy microbiome communities. Its lead clinical-stage products are LACTIN-V, a vaginally administered Lactobacillus crispatus CTV-05 therapy for recurrent bacterial vaginosis and preterm birth prevention, and CBM588/MO-03, an orally administered Clostridium butyricum strain used to enhance cancer immunotherapy response. The company also advances the MucoCept platform for mucosal viral protection and the Gassericin K7 bacteriocin for cervical cancer, supported by proprietary bacterial strain libraries, screening methods, and formulation/manufacturing technologies.

Is Osel a public or private company?

Osel is a private company. It is classified as venture growth investor backed and is currently operating.

When was Osel founded?

Osel was founded in 2003. It employs 11 to 50 people.

Where is Osel based?

Osel is headquartered in Mountain View, United States, in the North America region.

Who are Osel's main competitors?

Direct peers on record are Evelo Biosciences, Seres Therapeutics, MaaT Pharma, Finch Therapeutics, Vedanta Biosciences, Assembly Biosciences, 4D Pharma (AbbVie), Ferring Pharmaceuticals (Rebiotix), Axial Therapeutics and Kaleido Biosciences.

Does Osel have an API?

No public API is recorded for Osel.

What industry is Osel in?

Osel's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogOsel Inc. and March of Dimes Announce Groundbreaking Phase 2b Trial of Microbiome-based Therapy Targeting Preterm Birth PreventionOsel Inc., Imperial College London, and March of Dimes announced the FLIP-2 Phase 2b trial of LACTIN-V, a vaginal live biotherapeutic targeting preterm birth prevention. The double-blind study will enroll 360 high-risk pregnant women across four UK maternity units, following a positive Phase 1 pilot. The trial aims to be the first randomized controlled trial of a live biotherapeutic for preterm birth.BioSpaceOsel Enters Agreement with SWOG Cancer Research Network for First-Ever Pivotal Trial of a Microbiome-Based Therapy in OncologyOsel Inc. announced a clinical trial agreement with SWOG Cancer Research Network for a pivotal Phase 3 trial of its microbiome-based oncology candidate MO-03 in combination with standard immuno-oncology regimens for advanced and metastatic renal cell carcinoma (mRCC). The BIOFRONT trial, supported by the National Cancer Institute, will enroll approximately 700 patients across up to 150 SWOG sites in the United States, comparing MO-03 plus approved IO therapy versus placebo plus IO, with trial initiation slated for Q1 2026. This marks the first-ever pivotal trial of a microbiome-based oral therapy in oncology, building on prior Phase 1 studies showing statistically significant improvements in response rates and progression-free survival without added toxicity.PR NewswireHuman Microbiome Industry Analysis, 2014-2024 - Increasing Collaboration Between Market Players and AcademiaResearchAndMarkets.com published a global human microbiome market report covering the 2014-2024 period, with the market valued at USD 351.81 million in 2018, segmented by product type, disease application, and regional markets. The report identifies North America as the largest regional market driven by favorable reimbursement policies and high healthcare awareness. The analysis includes market sizing, forecasts, competitive landscape, and strategic assessments for companies including OptiBiotix Health, Metabiomics, OSEL Inc., PureTech Health, 4D Pharma, Synlogic Inc., BaseClear BV, Rebiotix Inc., Ritter Pharmaceuticals, and Assembly Bioscience Inc.